Sagefield Capital’s Blueprint Medicines BPMC Stock Holding History

Sagefield Capital’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-9,600	Closed	-$1.23M	–	112
2025 Q2	$1.23M	Buy	+9,600	New	+$997K	0.17%	70

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Sagefield Capital's BPMC Position: Q3 2025 in Review

Sagefield Capital sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 9,600 shares — an estimated $1.23M sold.

Sagefield Capital first reported a position in BPMC in Q2 2025 and held it in 1 quarter. The position peaked at $1.23M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Sagefield Capital reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Sagefield Capital sold 9,600 Blueprint Medicines shares in Q3 2025, an estimated $1.23M.
Sagefield Capital first reported a position in Blueprint Medicines in Q2 2025 and held it in 1 quarter.
Sagefield Capital's Blueprint Medicines position peaked at $1.23M in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Sagefield Capital's 13F filing for Q3 2025, filed 14 Nov 2025.